Braidwell LP Grows Position in Oric Pharmaceuticals, Inc. $ORIC

Braidwell LP boosted its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 7.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,214,540 shares of the company’s stock after buying an additional 86,500 shares during the quarter. Braidwell LP’s holdings in Oric Pharmaceuticals were worth $13,153,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ORIC. BlackRock Inc. purchased a new stake in shares of Oric Pharmaceuticals during the 2nd quarter valued at about $73,904,000. Vanguard Group Inc. raised its holdings in shares of Oric Pharmaceuticals by 48.8% during the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock valued at $55,802,000 after purchasing an additional 1,525,445 shares during the last quarter. State Street Corp raised its holdings in shares of Oric Pharmaceuticals by 77.1% during the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock valued at $34,834,000 after purchasing an additional 1,854,458 shares during the last quarter. Orbimed Advisors LLC lifted its position in Oric Pharmaceuticals by 305.0% during the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock valued at $43,701,000 after purchasing an additional 2,742,475 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Oric Pharmaceuticals by 14.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company’s stock worth $26,955,000 after purchasing an additional 423,795 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Insider Activity at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 77,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the completion of the transaction, the chief financial officer owned 69,828 shares in the company, valued at approximately $955,945.32. This represents a 52.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus began coverage on shares of Oric Pharmaceuticals in a research note on Friday, June 12th. They set a “buy” rating and a $14.00 target price for the company. The Goldman Sachs Group raised Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Friday, May 15th. HC Wainwright boosted their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. Finally, Benchmark reiterated a “buy” rating on shares of Oric Pharmaceuticals in a research note on Monday, June 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.45.

Oric Pharmaceuticals Price Performance

Shares of ORIC stock opened at $13.13 on Thursday. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -9.73 and a beta of 1.00. Oric Pharmaceuticals, Inc. has a one year low of $7.23 and a one year high of $14.93. The company’s fifty day moving average price is $12.09 and its 200-day moving average price is $10.78.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02). Equities research analysts expect that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.

Oric Pharmaceuticals Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.